Key facts
- GSK is acquiring Nuvalent for $10.6 billion, its largest acquisition ever.
- The deal aims to strengthen GSK's oncology drug portfolio with two lung cancer treatments.
- Nuvalent's treatments target ROS1- and ALK-positive mutations.
- The acquisition is expected to close in the third quarter.
- This move marks GSK's significant return to the oncology sector after exiting it previously.
GSK has agreed to acquire U.S. biotech firm Nuvalent for $10.6 billion, marking its largest acquisition to date and a significant step in rebuilding its oncology business. The deal, codenamed Project Nashville, aims to accelerate GSK's presence in cancer treatments by adding two late-stage lung cancer drugs targeting ROS1- and ALK-positive mutations.
This strategic move, expected to close in the third quarter, aligns with CEO Luke Miels' plan to expand in oncology, a sector GSK largely exited a decade ago. The acquisition is intended to help offset anticipated sales declines from patent expirations on its HIV drug dolutegravir later this decade. Analysts estimate GSK's total drug sales at £34 billion ($45.53 billion) this year.
The Nuvalent deal builds on GSK's previous, smaller investments in oncology, including the 2018 acquisition of Tesaro and the purchase of Sierra Oncology. Investors like James Eugene of Verso Investment Management view Nuvalent as a substantial addition to GSK's oncology rebuild, while others, such as Elena Meng of Gabelli Funds, acknowledge the established oncology strategy but highlight the unprecedented size of this commitment.
Sources close to the deal indicated competition for Nuvalent, contributing to the 40% premium paid over its pre-announcement closing price. The company was attractive due to its late-stage oncology assets nearing approval. Some investors believe GSK's prior divestment of its oncology franchise in 2015 was a strategic misstep, and the current return to the sector under Miels and his predecessor Emma Walmsley is seen as a correction.
Markus Manns of Union Investment anticipates Nuvalent's de-risked products could achieve $3 billion to $4 billion in peak sales, aiding GSK in reaching its £40 billion sales target by 2031. While GSK does not aim to rival giants like Merck, AstraZeneca, or Roche across all oncology areas, it sees the sector as a key growth opportunity. GSK's chief scientific officer, Tony Wood, previously stated that a specialty business without oncology is incomplete.
GSK will need to demonstrate that Nuvalent's lung cancer treatments can compete effectively with established drugs from Pfizer and Roche, particularly regarding efficacy and tolerability. Analysts at Barclays noted that while the acquisition makes strategic sense, neither asset appears to have "mega blockbuster" potential. GSK, however, believes these therapies could offer younger patients longer treatment durations with fewer side effects. Fund manager Ketan Patel suggests GSK may need further acquisitions to truly compete in the oncology space, as it is currently playing catch-up to market leaders.